



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.  
P1099R1C1

Serial No.  
09/863,693

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Arathoon

Filing Date  
23 May 2001

Group  
Unknown *1672 SR*

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>SR</i>	* 1	4,816,567	28.03.89	Cabilly et al.	-	-	-
<i>SR</i>	* 2	5,116,964	26.05.92	Capon et al.	-	-	-

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>SR</i>	* 3	314,317	03.05.89	EPO	/	/	/
	* 4	WO 89/02922	06.04.89	PCT			
	* 5	WO 91/08298	13.06.91	PCT			
	* 6	WO 92/10209	25.06.92	PCT			
	* 7	WO 92/22653	23.12.92	PCT			
	* 8	WO 93/06217	01.04.93	PCT			
	* 9	WO 93/11162	10.06.93	PCT			
	*10	WO 96/27011	06.09.96	PCT			
	*11	WO 96/37621	28.11.96	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>SR</i>	*12	Barton, "Protein sequence alignment and database scanning" <u>Protein Structure Prediction</u> pps. 31-63 (1996)
	*13	Berg et al., "Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain" <u>Proc. Natl. Acad. Sci. USA</u> 88:4723-4727 (June 1991)
	*14	Berman et al., "Protection from Genital Herpes Simplex Virus Type 2 Infection by Vaccination with Cloned Type 1 Glycoprotein D" <u>Science</u> 227(4693):1490-1492 (March 22, 1985)
	*15	Byrn et al., "Biological Properties of a CD4 Immunoaderhin" <u>Nature</u> 344:667-670 (April 12, 1990)
	*16	Carter et al., "Engineering Subtilisin BPN' for Site-Specific Proteolysis" <u>Proteins: Struct. Funct., Genet.</u> 6:240-248 (1989)
	*17	Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" <u>Bio/Technology</u> 10:163-167 (1992)
	*18	Carter, P. et al., "Humanization of an anti-p185 <sup>HER2</sup> antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992)
	*19	Chamow et al., "A Humanized, Bispecific Immunoaderhin-Antibody That Retargets CD3 <sup>+</sup> Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)
	*20	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)
	*21	Clackson et al., "Making antibody fragments using phage display libraries" <u>Nature</u> 352:624-628 (1991)
	*22	de Kruif et al., "Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library" <u>Journal of Biological Chemistry</u> 271(13):7630-7634 (March 29, 1996)

Examiner *[Signature]*

Date Considered  
*10/1/02*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1099RIC1

Serial No.

09/863,693

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Arathoon

Filing Date

23 May 2001

Group

Unknown

16-2

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

SR	*23	Dietsch et al., "Bispecific Receptor Globulins, Novel Tools for the Study of Cellular Interactions" <u>Journal of Immunological Methods</u> 162:123-132 (1993)
	*24	Ellison et al., "The nucleotide sequence of a human immunoglobulin C $\gamma$ 1 gene" <u>Nucleic Acids Research</u> 10(13):4071-4079 (1982)
	*25	Ellman et al., "Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins" <u>Meth. Enzym.</u> 202:301-336 (1991)
	*26	Panger et al., "Bispecific Antibodies" <u>Critical Reviews in Immunology</u> 12(3,4):101-124 (1992)
	*27	Peng et al., "Aligning Amino Acid Sequences: Comparison of Commonly Used Methods" <u>J. Mol. Evol.</u> 21:112-125 (1985)
	*28	Peng et al., "Progressive Alignment and Phylogenetic Tree Construction of Protein Sequences" <u>Methods in Enzymology</u> 183:375-387 (1990)
	*29	Peng et al., "Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees" <u>J. Mol. Evol.</u> 25:351-360 (1987)
	*30	Pigini et al., "In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Denaturation" <u>J. Mol. Biol.</u> 239:68-78 (1994)
	*31	George et al., "Current Methods in Sequence Comparison and Analysis" <u>Macromolecular Sequencing and Synthesis</u> pps. 127-149 (1988)
	*32	Griffiths et al., "Isolation of High Affinity Human Antibodies Directly From Large Synthetic Repertoires" <u>EMBO Journal</u> 13:3245-3260 (1994)
	*33	Gruber et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia Coli" <u>Journal of Immunology</u> 152:5368-5374 (1994)
	*34	Hammerling et al., "Use of hybrid antibody with anti- $\gamma$ G and anti-ferritin specificities in locating cell surface antigens by electron microscopy" <u>Journal of Experimental Medicine</u> 128:1461-1469 (1968)
	*35	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" <u>J. Mol. Biol.</u> 226:889-896 (1992)
	*36	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)
	*37	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , 5th edition, Bethesda, MD:NIH Vol. 1:688-696 (1991)
	*38	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" <u>Journal of Immunology</u> 148(5):1547-1553 (1992)
	*39	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)
	*40	Le Doussal et al., "Bispecific Monoclonal Antibody-Mediated Targeting of an Indium-111-Labeled DTPA Dimer to Primary Colorectal Tumors: Pharmacokinetics, Biodistribution, Scintigraphy and Immune Response" <u>J. Nucl. Med.</u> 34:1662-1671 (1993)
	*41	Le Doussal et al., "Bispecific-Antibody-Mediated Targeting of Radiolabeled Bivalent Haptens: Theoretical, Experimental and Clinical Results" <u>Int. J. Cancer Suppl.</u> 7:58-62 (1992)
↓	*42	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling" <u>Bio. Technology</u> 10:779-783 (1992)

Examiner

Date Considered

Jm 10/11/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

SEP 10 2001

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1099R1C1

Serial No

09/863,693

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Arathoon

Filing Date

23 May 2001

Group

Unknown

1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

SR	*43	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*44	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)
	*45	Nissim et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents" <u>EMBO Journal</u> 13(3):692-698 (1994)
	*46	Nolan et al., "Bifunctional antibodies: concept, production and applications" <u>Biochimica et Biophysica Acta</u> 1040:1-11 (1990)
	*47	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
	*48	Ridgway et al., "'Knobs into holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization" <u>Protein Engineering</u> 9(7):617-621 (1996)
	*49	Rodrigues et al., "Engineering a humanized bispecific F(ab') <sub>2</sub> fragment for improved binding to T cells" <u>Int. J. Cancer</u> (Suppl.) 7:45-50 (1992)
	*50	Segal et al., "Targeting and Activation of Cytotoxic Lymphocytes" <u>Chem. Immunol.</u> 47:179-213 (1989)
	*51	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>Journal of Experimental Medicine</u> 175:217-225 (Jan 1, 1992)
	*52	Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease" <u>Clin. Exp. Immunol.</u> 79:315-321 (1990)
	*53	Stickney et al., "Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma" <u>Cancer Research</u> 51:6650-6655 (1991)
	*54	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
	*55	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)
	*56	Waterhouse et al., "Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires" <u>Nucleic Acids Research</u> 21:2265-2266 (1993)
	*57	Weiner et al., "A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16" <u>Cancer Research</u> 53:94-100 (1993)
	*58	Wells and Powers, "In vivo formation and stability of engineered disulfide bonds in subtilisin" <u>J. Biol. Chemistry</u> 261(14):6564-6570 (May 15, 1986)
	*59	Zhu et al., "Remodeling domain interfaces to enhance heterodimer formation" <u>Protein Science</u> 6(4):781-788 (Apr 1997)

Examiner

Date Considered

10/1/02

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.